Dual endothelin receptor antagonism increases resting energy expenditure in people with increased adiposity.

ABSTRACT: Increased adiposity is associated with dysregulation of the endothelin system, both of which increase the risk of cardiovascular disease (CVD). Preclinical data indicate that endothelin dysregulation also reduces resting energy expenditure (REE). The objective was to test the hypothesis that endothelin receptor antagonism will increase REE in people with obesity compared with healthy weight individuals. Using a double blind, placebo-controlled, crossover design, 32 participants [healthy weight (HW): n = 16, BMI: 21.3 ± 2.8 kg/m², age: 26 ± 7 yr and overweight/obese (OB): n = 16, BMI: 33.5 ± 9.5 kg/m², age: 31 ± 6 yr] were randomized to receive either 125 mg of bosentan (ET_A/B antagonism) or placebo twice per day for 3 days. Breath-by-breath ga

SUBMITTER: Derella CC 

PROVIDER: S-EPMC9126219 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature